文献速递前列腺癌

ExoDx前列腺检测作为高级别前列腺癌结局预测指标的中期分析

ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-05-16

这项前瞻性、盲法、随机、多中心临床效用研究于2017年6月至2018年5月纳入1049名≥50岁、PSA 2-10 ng/mL、正考虑前列腺活检的男性,随机分为EPI组与标准治疗(SOC)组,仅EPI组在活检决策中获知EPI结果。2.5年随访时833例有随访数据,低危EPI评分(<15.6)者活检率更低、首次活检时间更长,且两臂低危EPI评分者高级别前列腺癌(HGPC)发生率均低于高危EPI评分者。

要点

  • EPI组低危评分者活检率44.6% vs 高危评分者79.0%(p<0.001)。
  • EPI组低危评分者首次活检平均时间216天 vs 高危评分者69天(p<0.001)。
  • 两臂低危EPI评分者HGPC 7.9% vs 高危EPI评分者26.8%(p<0.001)。

核心结论

  • 接受EPI低危评分(<15.6)的男性显著延迟首次活检时间,且在初始研究后2.5年时仍处于极低病理风险。
  • EPI检测的风险分层识别出了标准治疗未发现低危患者。

研究设计与样本

  • 前瞻性、盲法、随机、多中心临床效用研究,2017年6月至2018年5月开展(NCT03235687)。
  • 从1049名≥50岁、PSA 2-10 ng/mL、正考虑前列腺活检的男性收集尿液样本,随机分为EPI组与标准治疗(SOC)组。
  • 所有患者均接受EPI检测,但仅EPI组在活检决策过程中获知结果。
  • 在低(<15.6)或高(≥15.6)EPI评分者中评估临床结局、活检时间与病理。
  • 2.5年时833例患者有随访数据。

主要发现

  • EPI组中,低危EPI评分者活检率低于高危EPI评分者(44.6% vs 79.0%,p < 0.001)。
  • SOC组中,无论EPI评分高低,活检率相同(59.6% vs 58.8%,p = 0.99)。
  • EPI组中,低危EPI评分者从EPI检测到首次活检的平均时间长于高危EPI评分者(216 vs. 69天;p < 0.001)。
  • EPI组低危EPI评分者首次活检时间长于SOC组低危EPI评分者(216 vs 80天;p < 0.001)。
  • 2.5年时,两臂低危EPI评分者的HGPC少于高危EPI评分者(7.9% vs 26.8%,p < 0.001),且EPI组发现HGPC比SOC组多21.8%。

关键数值与推荐

  • EPI低危评分定义为<15.6,高危评分定义为≥15.6。
  • EPI组低危评分者活检率44.6% vs 高危评分者79.0%(p < 0.001)。
  • SOC组低危评分者活检率59.6% vs 高危评分者58.8%(p = 0.99)。
  • EPI组低危评分者首次活检平均时间216天 vs 高危评分者69天(p < 0.001)。
  • 两臂低危EPI评分者HGPC 7.9% vs 高危EPI评分者26.8%(p < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patient outcomes were assessed based on a pre-biopsy ExoDx Prostate (EPI) score at 2.5 years of the 5-year follow-up of ongoing prostate biopsy Decision Impact Trial of the ExoDx Prostate (IntelliScore). METHODS: Prospective, blinded, randomized, multisite clinical utility study was conducted from June 2017 to May 2018 (NCT03235687). Urine samples were collected from 1049 men (≥50 years old) with a PSA 2-10 ng/mL being considered for a prostate biopsy. Patients were randomized to EPI vs. standard of care (SOC). All had an EPI test, but only EPI arm received results during biopsy decision process. Clinical outcomes, time to biopsy and pathology were assessed among low (<15.6) or high (≥15.6) EPI scores. RESULTS: At 2.5 years, 833 patients had follow-up data. In the EPI arm, biopsy rates remained lower for low-risk EPI scores than high-risk EPI scores (44.6% vs 79.0%, p < 0.001), whereas biopsy rates were identical in SOC arm regardless of EPI score (59.6% vs 58.8%, p = 0.99). Also in the EPI arm, the average time from EPI testing to first biopsy was longer for low-risk EPI scores compared to high-risk EPI scores (216 vs. 69 days; p < 0.001). Similarly, the time to first biopsy was longer with EPI low-risk scores in EPI arm compared to EPI low-risk scores in SOC arm (216 vs 80 days; p < 0.001). At 2.5 years, patients with low-risk EPI scores from both arms had less HGPC than high-risk EPI score patients (7.9% vs 26.8%, p < 0.001) and the EPI arm found 21.8% more HGPC than the SOC arm. CONCLUSIONS: This follow-up analysis captures subsequent biopsy outcomes and demonstrates that men receiving EPI low-risk scores (<15.6) significantly defer the time to first biopsy and remain at a very low pathologic risk by 2.5-years after the initial study. The EPI test risk stratification identified low-risk patients that were not found with the SOC.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Tutrone R, Lowentritt B, Neuman B, et al. ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis. Prostate Cancer Prostatic Dis. 2023. PMID: 37193776. doi:10.1038/s41391-023-00675-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。